Protocol Ledger

NCT06521255 · Phase III · RECRUITING

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffu

Interventional Phase III clinical trial protocol NCT06521255 sponsored by Beijing InnoCare Pharma Tech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-07 Enrollment: 244 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06521255
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)244 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06521255
Protocol FieldVerified Registry Value
NCT IdentifierNCT06521255
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment244 participants (ESTIMATED)
Registered Start Date2024-05-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06521255
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI